ProCE Banner Activity

Phase II Trial of Oral Weekly Islatravir (ISL) + Lenacapavir (LEN) in Virologically Suppressed People Living With HIV

Conference Coverage

In this open-label, active-controlled phase II trial, treatment with once-weekly oral ISL and LEN maintained high rates of virologic suppression without significant alterations to CD4+ cell counts or absolute lymphocyte counts vs BIC/FTC/TAF at 24 weeks.  

Released: March 08, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare